I am/have/had
I am looking for
Advanced Filters
Found 2 clinical trials
NUVOLA TRIAL Open-label Multicentre Study
OLAPARIB in BRCA mutation carriers Olaparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor that causes synthetic lethality in BRCA1/2-deficient tumour cells. In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib maintenance treatment significantly improved the duration of progression-free survival compared with placebo (hazard ratio [HR] 0.35 [95% CI …
luteinizing hormone
oophorectomy
peritoneal cancer
ovarian cancer
tumor debulking
- 0 views
- 19 Feb, 2024
Niraparib/TTFields in GBM
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
glioblastoma
recurrent glioblastoma
renal function
karnofsky performance status
renal function test
- 0 views
- 19 Feb, 2024